New insight into the management of psychoemotional risk factors in patients with cardiovascular diseases in middle and young age

Affective spectrum disorders, such as depression and anxiety disorders, are important psychoemotional risk factors for the development and complicated course of many common chronic non-communicable diseases, including cardiovascular ones: arterial hypertension, coronary heart disease, chronic heart failure, atrial fibrillation, acute coronary syndrome, etc. A feature of this comorbidity is the significant impact of psychoemotional factors on the motivation and adherence of patients to a healthy lifestyle, as well as various drug treatment options, which involves an increased risk of complications and, as a consequence, increased healthcare costs. The topicality of the issues of screening and management of psychoemotional disorders in the internist practice arises from a variety of reasons. On the one hand, it is a high incidence of these disorders in patients with cardiovascular diseases, including young and middle-aged ones, which is associated with a deterioration in the quality of life and an increased risk of complications and adverse outcomes in the future. On the other hand, it is caused by insufficient level of awareness among doctors about new possibilities for the management of the psychoemotional state of such patients. This review presents data on the effectiveness and safety of therapy of psychoemotional disorders in patients with various CVDs with a drug containing D,L-hopanthenic acid (rat-hopanthenic acid) as an active substance of the nootranquilizer class, which has a wide range of clinical effects, including a beneficial effect not only on psychoemotional sphere, but also on cognitive functions. The prospects for prescribing a D,L-hopantenic acid drug to young and middle-aged patients with CVD, which reduces the drug burden on the patient and provides high quality of life for patients both in hospital and at subsequent stages of treatment, are discussed. The key point is availability of an option for prolonged use of D,L-hopanthenic acid drug without any risk of addiction, withdrawal syndrome or hyperstimulation, which is an important clinical aspect of drug therapy for patients with CVD, especially in young and middle age.

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/S0140-6736(19)31047-5.15.

2. Drapkina OM, Kontseva AV, Kalinina AM, Avdeev SN, Agaltsov MV, Alexandrova LM et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(4):3235. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3235.

3. Shishkova VN. Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy. Meditsinskiy Sovet. 2023;(13):256–262. (In Russ.) https://doi.org/10.21518/ms2023-230.

4. Drapkina OM, Shishkova VN, Kotova MB. Psychoemotional risk factors for non-communicable diseases in outpatient practice. Methodological recommendations for therapists. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(10):97–117. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3438.

5. Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–1196. https://doi.org/10.1007/s00392-019-01488-w.

6. Shishkova VN. Cognitive and emotional disorders in patients with chronic heart failure: prospects for detection and correction. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):87–93. (In Russ.) https://doi.org/10.14412/2074-2711-2022-3-87-93.

7. Ronaldson A, de la Torre JA, Prina M, Armstrong D, Das-Munshi J, Hatch S et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021;8:100149. https://doi.org/j.lanepe.2021.100149.

8. Chazov EI, Oganov RG, Pogosova GV, Shalnova SA, Skazin NV, Romasenko LV. Clinical and epidemiological program for studying depression in cardiological practice in patients with arterial hypertension and coronary heart disease (COORDINATE): results of the therapeutic part of a multicenter study. Serdtse: Zhurnal dlya Praktikuyushchikh Vrachey. 2007;33(1):44–48. (In Russ.)

9. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am Heart J. 2015;170(6):1105–1115. https://doi.org/10.1016/j.ahj.2015.09.013.

10. Shishkova VN, Ustarbekova DB, Shishkov VA, Imamgayazova KE, Kapustina LA. Psycho-emotional disorders in chronic heart failure patients. Therapy. 2022;1(8):44–49. (In Russ.) https://doi.org/10.18565/therapy.2022.1.44-49.

11. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439–448. https://doi.org/10.1016/j.jpsychores.2014.10.001.

12. Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687–1696. https://doi.org/10.1093/eurheartj/ehy913.

13. Daskalopoulou M, George J, Walters K, Osborn DP, Batty GD, Stogiannis D et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1. 9 Million Women and Men. PLoS ONE. 2016;11(4):e0153838. https://doi.org/10.1371/journal.pone.0153838.

14. Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: a systematic review and meta-analysis. J Psychosom Res. 2016;90:10–32. https://doi.org/10.1016/j.jpsychores.2016.09.003.

15. Kessing D, Denollet J, Widdershoven J, Kupper N. Psychological determinants of heart failure self-care: systematic review and meta-analysis. Psychosom Med. 2016;78(4):412–431. https://doi.org/10.1097/PSY.0000000000000270.

16. Shishkova VN, Dranitsyna YuG, Drapkina OM. Algorithms for the management of patients with anxiety in the internist’s practice. Cardiovascular Therapy and Prevention (Russian Federation). 2023;22(2):3526. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3526.

17. Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Höfer S et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290–1306. https://doi.org/10.1177/2047487314543075.

18. Peters A, McEwen BS. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015;56:139–150. https://doi.org/10.1016/j.neubiorev.2015.07.001.

19. Александровский ЮА, Незнанов НГ (ред.). Психиатрия. Национальное руководство. М.: ГЭОТАР-Медиа; 2020. 1008 с.

20. Shishkova VN. Simple and effective solutions in the correction of anxiety and stress. Meditsinskiy Sovet. 2023;17(3):161–167. (In Russ.) https://doi.org/10.21518/ms2023-023.

21. Shishkova VN. Strategy for the management and prevention of psychoemotional disorders in the GP’s practice. Meditsinskiy Sovet. 2023;17(6):76–82. (In Russ.) https://doi.org/10.21518/ms2023-077.

22. Шишкова ВН, Драпкина ОМ. Схема «алгоритм ведения пациентов с психоэмоциональными нарушениями». Патент RU 137449, 06.07.2023. Режим доступа: https://gnicpm.ru/wp-content/uploads/2023/07/137449.eod_.pdf.

23. Boehm JK, Kubzansky LD. The heart’s content: The association between positive psychological well-being and cardiovascular health. Psychol Bull. 2012;138(4):655–691. https://doi.org/10.1037/a0027448.

24. Müller-Riemenschneider F, Meinhard C, Damm K, Vauth C, Bockelbrink A, Greiner W, Willich SN. Effectiveness of nonpharmacological secondary prevention of coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2010;17(6):688–700. https://doi.org/10.1097/HJR.0b013e32833a1c95.

25. Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. 2009;2(1):25–32. https://doi.org/10.1161/CIRCOUTCOMES.108.812859.

26. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med. 2011;171(2):134–140. https://doi.org/10.1001/archinternmed.2010.510.

27. Virgili M. Mindfulness-based interventions reduce psychological distress in working adults: A meta-analysis of intervention studies. Mindfulness. 2015;6(2):326–337. https://doi.org/10.1007/s12671-013-0264-0.

28. Dehdari T, Heidarnia A, Ramezankhani A, Sadeghian A, Ghofranipour F. Effects of progressive muscular relaxation training on quality of life in anxious patients after coronary artery bypass graft surgery. Indian J Med Res. 2009;129(5):603–608. Available at: https://pubmed.ncbi.nlm.nih.gov/19675392.

29. Shi L, Zhang D, Wang L, Zhuang J, Cook R, Chen L. Meditation and blood pressure. J Hypertens. 2017;35(4):696–706. https://doi.org/10.1097/HJH.0000000000001217.

30. Blumenthal JA, Sherwood A, Smith PJ, Watkins L, Mabe S, Kraus WE et al. Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. Circulation. 2016;133(14):1341–1350. https://doi.org/10.1161/CIRCULATIONAHA.115.018926.

31. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(3):247–259. https://doi.org/10.1177/2047487317739978.

32. He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):919–926. https://doi.org/10.1007/s10741-019-09850-w.

33. Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33(6):745–751. https://doi.org/10.1093/eurheartj/ehr368.

34. Voronina TA, Litvinova SA. Pharmacological effects and clinical application of pantogam and pantogam active. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(8):132–139. (In Russ.) https://doi.org/10.17116/jnevro201711781132-139.

35. Ostroumova OD, Goloborodova IV, Fomina VM, Bondarets OV. Anxiety and depressive disorders in cardiology practice. Possibilities of using. Consilium Medicum. 2018;20(12):23–29. (In Russ.) https://doi.org/10.26442/20751753.2018.12.000032.

36. Baranov AP, Strutynsky AV, Oynotkinova OS, Baranova AA, Trishina VV, Golubev YuYu, Kruzhalov AN. Possibilities of therapy of anxiety-depressive disorders in patients with chronic heart failure. Kardiologiya. 2016;24(9):572–578. (In Russ.)

37. Medvedev VE, Zverev KV, Epifanov AV, Lartseva OA, Zuikova NL, Frolova VI Possibilities of nootropic therapy of borderline mental disorders in patients with acute coronary syndrome in a cardiological hospital. Russian Archive of Internal Medicine. 2013;9(1):40–48. (In Russ.) https://doi.org/10.20514/2226-6704-2013-0-1-40-48.

38. Medvedev VE, Albantova KA. Pantogam is an asset in the treatment of neurotic, stress-related and somatoform disorders in patients of a cardiological hospital. Mental Disorders in General Medicine. 2009;(2):40–43. (In Russ.)

39. Medvedev VE, Epifanov AV. Therapy of neurotic, stress-related, and somatoform disorders in hypertension patients. Rossijskij Psihiatriceskij Zurnal. 2011;(1):55–61. (In Russ.) Available at: https://cyberleninka.ru/article/n/terapiya-nevroticheskih-svyazannyh-so-stressom-i-somatoformnyh-rasstroystv-u-patsientov-s-gipertonicheskoy-boleznyu?ysclid=lmjai3optd863221237.

40. Kamchatnov PR. Correction of cognitive and emotional disorders in patients with arterial hypertension. RMJ. Medical Review. 2019;3(7):28–29. (In Russ.) Available at: https://www.rmj.ru/articles/kardiologiya/Korrekciya_kognitivnyh_i_emocionalynyh_rasstroystv_u_bolynyh_arterialynoy_gipertoniey/.

41. Smulevich AB, Volel’ BA, Ternovaia ES, Nikitina YuM. Pantogam active (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(12):40–49. (In Russ.) https://doi.org/10.17116/jnevro201511511240-49.

42. Geht AB, Kanaeva LS, Avedisova AS, Marachev MP, Zakharova KV, Dashkina GK, Kulikova EV. Possible applications of rac-hopantenic acid in the treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2016;116(11):45–57. (In Russ.) https://doi.org/10.17116/jnevro201611611145-57.

43. Shishkova VN, Zotova LI. The use of D-, L-hopanthenic acid in the treatment of cognitive and anxiety disorders in women with chronic cerebral ischemia and menopausal syndrome. RMJ. 2015;(24):1470–1475. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Primenenie_D-_L-gopantenovoy_kisloty_v_terapiikognitivnyh_i_trevoghnyh_rasstroystv_u_ghenschins_hronicheskoy_ishemiey_golovnogo_mozgai_klimaktericheskim_sindromom/?ysclid=lmjas70gpn378613852.

44. Kanaeva LS, Vazagaeva TI, Yastrebova VV. Prospects for the use of Pantogam active in patients with asthenic disorders. Psikhiatriya i Psikhofarmakoterapiya. 2009;11(6):34–39. (In Russ.)

45. Shishkova VN. Place of arterial hypertension in brain lesion development – from minor cognitive disorders to dementia. Systemic Hypertension. 2014;11(1):45–51. (In Russ.) Available at: https://www.syst-hypertension.ru/jour/article/view/336.

46. Shishkova VN, Adasheva TV. Modern view on the mechanisms of cognitive impairment development in patients with cardiovascular diseases and the possibility of their correction. Nervous Diseases. 2021;(2):41–46. (In Russ.) https://doi.org/10.24412/2226-0757-2021-12317.

47. Shishkova VN. Cognitive disorders in patients with cerebrovascular diseases in therapeutic practice: diagnostic and management algorithms. Meditsinskiy Sovet. 2022;16(23):33–40. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-23-33-40.